Diabetic Retinopathy, Open-angle Glaucoma
Conditions
Brief summary
This study is a multi-armed protocol designed to evaluate the safety and efficacy of two different combinations of nutritional supplements (study drug) (Glauco-Health and Glauco-Select) chosen for their potential to protect retinal ganglion cells against oxidative stress, low-grade inflammation, and mitochondrial dysfunction in patients with open-angle glaucoma and diabetic retinopathy. Oxidative stress and retinal cellular dysfunction will be measured using a Retinal Metabolic Analyzer (RMA) in this randomized, single center, double masked study. Patients with glaucoma will be divided into three treatment arms randomized to receive either Glauco-Health, Glauco-Select, or placebo.
Detailed description
This investigation is using over the counter supplements. The investigation is intended only to evaluate their effect on the structure or function of mitochondria as it relates to the autofluorescence imaging being conducted in the study. They are not being studied to evaluate their ability to diagnose, cure, mitigate, or treat disease. These ingredients in these combinations of nutritional supplements have also been reported beneficial in diabetic retinopathy. Patients with diabetic retinopathy will be added later as an additional arm and an amendment to this effect will be submitted when that portion of the study is ready to be initiated. That amendment will include background material, appropriate inclusion and exclusion criteria, informed consent, and references. At the current time, only the glaucoma proposal and glaucoma patients will be enrolled according to this submitted protocol.
Interventions
DRUGGlaucoHealth
Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
DRUGGlaucoSelect
Containing curcumin, bilberry extract, and grape seed extract
DRUGPlacebo
No active ingredients
Sponsors
The New York Eye & Ear Infirmary
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female of any race, at least 18 years of age. 2. Has provided verbal and written informed consent. 3. Able and willing to follow instructions, including participation in all study assessments and visits. 4. Eyes with moderate to severe primary open-angle glaucoma will be enrolled. Glaucoma severity will be graded using the WHO glaucoma staging system. 1. OAG eyes are defined by clinical findings consistent with glaucomatous optic neuropathy (Ex: thinning, excavation, rim erosion or notching of the neuroretinal rim) 2. Reproducible visual field defects on at least three examinations as measured by a glaucoma hemifield test (GHT) result outside normal limits and/or the presence of at least three consecutive test points on the pattern deviation plot with P\<1% and at least one at P\<0.05%, not including points on the edge of the field. 5. Both eyes will be enrolled. 6. Refractive error ≤5 diopters and astigmatism ≤3 diopters
Exclusion criteria
1. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assignment, such as age-related macular degeneration, macular dystrophy, retinopathy from systemic diseases, marked ocular media opacities that obscure retinal imaging, etc. 2. BCVA \<20/200 3. Concurrent conjunctivitis, keratitis or uveitis 4. History of penetrating ocular trauma. 5. Subject uncooperativeness that restricts adequate examination of IOP, ocular fundus or anterior chamber. 6. Has a condition or history that, in the opinion of the investigator, may interfere significantly with the subject's participation in the study. 7. A woman who is pregnant, nursing an infant, or planning a pregnancy 8. Has a known adverse reaction and/or sensitivity to the study drug or its compound. a. Including: alpha lipoic acid, citicoline, Co-enzyme Q-10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, green tea extract, and bilberry extract. 9. Currently enrolled in an investigational drug study or has used an investigational drug within 30 days prior to Visit 1. 10. Is planning on having surgery at any time throughout the study duration (90 days from initiation) 11. Is currently receiving chemotherapy 12. Has a history of diabetes mellitus, seizure(s), bleeding disorder(s) 13. Has a history of uncontrolled hypertension (≥180 systolic or ≥110 diastolic on two successive measures) 14. Has a history of any radiation around the eyes 15. Currently using anticoagulant/antiplatelet drugs (patients on coumadin, clopidogral (Plavix), and plasugrel (Effient) will be excluded but that patients taking aspirin will be allowed) 16. Unwilling or unable to cease using other anti-oxidative agents or drugs. 17. Dilated pupil diameter less than 5 millimeters 18. Fluorescein drop administration within 8 hours before imaging 19. History of cataract surgery in the 3 months prior to imaging 20. History of any other intraocular surgery within 4 months prior to enrollment 21. Corticosteroid or immunosuppressive therapy within 6-months prior to imaging 22. Lens opacity ≥grade 3 on ARLNS on standard photographs (Appendix 6) 23. History of vitrectomy 24. Monocular patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Flavoprotein fluorescence index | 3 months | Average Intensity and Average Curve Width |
Secondary
| Measure | Time frame |
|---|---|
| Visual acuity | 3 months |
| Humphrey visual field testing (24-2) | 3 months |
Countries
United States
Outcome results
None listed